RE:NO Institutional supportCorrect TXB, but on the upside Pharma are paying incredible premiums for late stage pipeline products. Every week there is a new precedent being set for projected revenue. These valuations are at historical highs, by a freaking mile. Whatever TST may be giving up in SP management they should be receiving back 5 fold in speculation of a partnership or buyout alone. Multiple partners have been through multiple open houses with multiple inspections and still no "acceptable" offers in this insane biotech market? HARD TO FATHOM. Maybe next weeks Journal of Urology article will ignite things. I always think that the"under the radar" story is charming in a simple apologetic hick Canadian kind of way, but MCNA is not under the radar for carnivores looking to buy revenue.